In September, the Swiss company released four core products under the Alastin brand in China, marking its debut in one of the world’s fastest-growing aesthetic skin care markets.
The increasing demand is driven by several factors, including a rapid rise in China’s medical aesthetics market, with projections indicating up to 15% annual growth in the next decade, according to the company.
“Consumers in the APAC region are becoming more informed and proactive about optimising outcomes from aesthetic treatments, and a cultural shift toward self-care and premium skin care means that consumers are investing in advanced, science-backed products that deliver visible results.
“Alastin’s launch in China is a direct response to this evolving landscape, offering a full-spectrum solution that meets both clinical and consumer needs,” Dr Alan Widgerow, Galderma’s Chief Scientific Officer, told CosmeticsDesign-Asia.
Following strong growth in North and Latin America, Australia, Ireland and the UK, Alastin is now accelerating its international expansion. The launch in China is the first to feature the brand’s refreshed look.
Beyond China, the brand sees significant opportunities in various APAC markets, including South Korea, Japan, Singapore, Thailand, and Australia.
“Some of these markets are characterised by a high demand for aesthetic procedures and advanced skin care, and a sophisticated consumer base that value innovation and efficacy.
“With our broad and diverse portfolio spanning dermatological skin care and injectable aesthetics, we are well-positioned to meet the evolving needs of this growing consumer base in Asia.”
Holistic, regenerative approach
The four core products are designed to cover all stages of the aesthetic journey — from pre-treatment preparation to post-procedure recovery and at-home maintenance skin care.
Each product is formulated to boost the skin’s natural regenerative abilities to help with skin recovery and improve overall results.
For instance, the Regenerating Skin Nectar helps to remodel the skin, with up to 27% faster healing at day 7, while the HA (Hyaluronic Acid) IMMERSE Serum provides deep hydration and supports skin barrier repair to prevent signs of ageing, with over 95% of consumers agreeing that their skin looks replenished and feels hydrated after a month of use.
“For those looking to enhance their post-procedure recovery, the INhance Serum can accelerate this and also optimise skin appearance following injectable treatments. In fact, it can provide up to 89% recovery after two weeks.
“We are also introducing the Restorative Skin Complex, a topical biostimulator that can help reduce visible signs of ageing and support long-term skin rejuvenation, to the Chinese market. I expect this product to be very popular in China, as 100% of users agreed that their skin looks more radiant and luminous,” Dr Widgerow said.This series of products advances aesthetic treatments from isolated procedures to full-spectrum management, reflecting Galderma’s holistic approach to skin care.
In addition, Dr Widgerow explained that Alastin’s efficacy is largely attributed to its proprietary TriHex Technology, which comprises a unique blend of peptides that stimulate elastin and collagen, working in synergy with the skin’s natural processes.
“This technology helps prepare and amplify the skin’s regenerative abilities, leading to a more youthful-looking complexion. The regenerative approach is especially valuable in perioperative skin care, where preparing the skin before procedures and aiding recovery afterward can really enhance aesthetic outcomes.
“For over 10 years, Alastin’s proprietary technologies and ingredients have led the way in regenerative skin care. These are strongly backed by science, with more than 50 international dermatological publications and 22 patents.”
Catering to multifaceted needs
According to Dr Widgerow, Galderma’s innovation strategy is rooted in regional relevance and scientific rigour.
“We recognise that skin needs vary widely across Asia due to differences in climate, lifestyle, genetics, and cultural preferences. Every skin story is unique, and we strive to embrace these differences and drive innovation to meet the vast spectrum of skin needs.”
To address the diversity of consumers, the company is investing in local research and clinical studies to understand specific skin needs. For example, it recently conducted a first-of-its-kind clinical study in China to investigate the impact of urban living on sensitive skin.
Additionally, it is collaborating with regional healthcare professionals and aesthetic experts through initiatives like the Galderma Aesthetic Injector Network (GAIN), fostering knowledge exchange and co-creation.
“In fact, last year we brought together over 650 healthcare professionals from 14 countries across APAC to share their knowledge and experiences. It was the largest GAIN event to date in the region, and it exemplifies our commitment to understanding the broad spectrum of needs here.
“By combining global science with local insights, we’re able to deliver tailored solutions that resonate with diverse consumers and elevate dermatological care across APAC.”
